19 results about "Braf genes" patented technology

The invention discloses an antigen polypeptide related to BRAF gene V600E mutation and application of the antigen polypeptide. On the basis of a classical tumor neoantigen affinity prediction technology, an advanced immunogenicity prediction AI algorithm is adopted to improve the accuracy of tumor neoantigen prediction; the antigen polypeptide related to BRAF gene V600E mutation is characterized in that a replacement peptide for enhancing immunogenicity is further excavated based on a biological information screening technology of amino acid editing, the sequence of the antigen polypeptide related to BRAF gene V600E mutation is shown as any one of SEQ ID NO: 1-3, and the antigen polypeptide can remarkably activate T cells specifically aiming at BRAF mutation of a human body and enhance the killing ability of the T cells to BRAF mutation tumor cells. Therefore, the antigen polypeptide obtained by the invention has good potential of polypeptide vaccines and good clinical transformation and disease prevention prospects.

The invention relates to the technical field of clinical molecular detection, and discloses a primer probe set and a kit for detecting colorectal cancer KRAS, NRAS and BRAF genes and application, the primer probe set is used for detecting a plurality of mutation sites of the KRAS, NRAS and BRAF genes, and the mutation sites comprise KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, NRAS G12D, NRAS Q61K, NRAS Q61R and BRAF V600E. According to the invention, the sensitivity and specificity of gene detection can be effectively improved, 11 mutation sites of KRAS, NRAS and BRAF genes can be simultaneously detected by one tube, the number of detected genes is large, the number of mutation sites is large, the coverage range is wide, reagent consumables are saved, the detection cost is low, the consumed time is short (1-2 hours), and the operation is convenient. The kit is high in sensitivity and specificity.

The invention provides a kit for detecting human BRAF gene V600E and TERT gene promoter mutation, and belongs to the technical field of biology. The kit comprises a primer, a probe, a 5 * PCR (Polymerase Chain Reaction)-Enhancer, a 10 * PCR Buffer, dNTP (Deoxyribonucleoside Triphosphate) Mix, MalTaq DNAPlyase, magnesium ions, DEPC (Diethylpyrocarbonate) water, a positive control and a negative control. According to the present invention, the ARMS-PCR detection technology is adopted to detect the specific gene mutation, and the target mutation site is identified by designing the specific primer and the probe, such that the detection specificity and the detection sensitivity are improved; by combining with a Taqman probe technology, the fluorescent signal change in the PCR amplification process can be monitored in real time, so that whether mutation of a BRAF V600E site, a TERT C228T site and a TERT C250T site exists or not is accurately judged; according to the method, pre-amplification of 15 cycles is adopted, then quantitative amplification of 30 cycles is adopted, and when the initial amount of the target DNA is very low, the copy number of the target DNA can be increased, so that the detection accuracy and sensitivity are further improved.

1. The name of the design product: kit (BRAF intestinal cancer gene detection typing kit). 2. The use of the design product: the design product is used for packaging reagents. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective view.

The present application relates to a primer for quantitative detection of V600E mutation in the human BRAF gene based on digital PCR, the primer comprising the nucleotide sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. Preferably, the probe comprises a wild-type probe of the V600E gene, a mutation site of the V600E gene (c.1799_1800delinsAT), a mutation site of the V600E gene (c.1799_1800delinsAC) and / or a mutation probe of the mutation site of the V600E gene (c.1798_1799delinsAA). The present invention combines the vibration droplet generation digital PCR (dPCR) technology and, through innovative methodological optimization (artificial sequence), demonstrates significant technical advantages and clinical application value in the detection of V600E mutation in the human BRAF gene.

The present invention belongs to the technical field of sequencing in gene therapy. Provided is a detection method for a rare-mutation BRAF gene. The sequencing method comprises: during an amplification process of the BRAF gene of a target sample fragment, adding a blocking primer matched with a wild-type template in the target sample fragment, so as to bind the blocking primer to a denatured wild-type template; and performing sequencing to obtain a sequencing result corresponding to the target sample fragment. During the process of making a sequencing template, the present invention uses the blocking primer to inhibit the wild-type template of the BRAF gene during the amplification process, so as to relatively increase the proportion of a mutant product, thereby achieving the purpose of accurately detecting samples with a lower mutation rate. Therefore, the present method is of an important significance for detecting rare mutations by using a Sanger sequencing method.

The application belongs to the field of biological medicine, and relates to a composition, a kit and application for thyroid cancer detection. The primer composition can be used for simultaneously detecting mutation or fusion of five gene sites of two genes, BRAF gene and RET-PTC gene, and can be used for detecting thyroid cancer and has high sensitivity and specificity. Meanwhile, the fluorescence PCR technology is adopted to improve detection efficiency, shorten detection time and realize precise diagnosis of thyroid cancer.

The present invention relates to a method for determining the efficacy of a drug treatment for a subject suffering from malignant melanoma, wherein said method comprises the steps of: (i) evaluation of the presence or absence of a genetic alteration in a BRAF gene, a. detecting the presence and / or quantity of at least one biomarker in a biological sample obtained from said subject, wherein said biomarker is BRAF V600 mutated protein and / or at least one immunoproteasome protein, and b. classifying the subject as having a high or low likelihood of responding to a drug treatment, based on the presence and / or quantity of said at least one biomarker, wherein in case the genetic alteration in the BRAF gene is present, the presence and / or quantity of at least one BRAF V600 mutated protein and at least one immunoproteasome protein is detected in said biological sample, and wherein in case the genetic alteration in the BRAF gene is not present, the presence and / or quantity of at least one immunoproteasome protein is detected in said biological sample.

The invention discloses a noninvasive exosome mRNA BRAF V600E mutation Tag-PCR (Tag-Polymerase Chain Reaction) detection method, which comprises the following steps: separating an exosome sample from a body fluid; the method comprises the following steps: by taking mRNA as a template, adding an exogenous reference gene and a primer pair for detecting the exogenous reference gene, and meanwhile, carrying out a first round of PCR amplification reaction by using a Tag-ARMS primer pair for specifically enriching exosome mRNA BRAF gene V600E mutation so as to form a PCR product; a PCR product is used as a template, a system without UNG enzyme is used for amplification, a primer pair for detecting a reference gene is added, a Tag primer pair for specifically enriching and detecting V600E mutation of the human exosome mRNA BRAF gene and a probe sequence are used at the same time, and then a second round of PCR amplification reaction is carried out; and judging the mutation state of the V600E site of the BRAF gene of the mRNA of the exosome sample.

The present invention relates to a compound for regulating the expression level and / or activity of the BRAF gene, and a composition comprising same. The compound and the composition are useful for preventing, treating, or alleviating BRAF-related diseases, disorders, and conditions.

Provided are methods for detecting urogenital malignancies in dogs. In some embodiments, the methods include identifying a deletion or single nucleotide substitution within a BRAF gene and / or within a MAP2K1 gene present in or isolated from a biological sample from a. dog, wherein the presence of the deletion or single nucleotide substitution within the BRAF gene and / or within the MAP2K1 gene detects a urogenital malignancy, optionally transitional cell carcinoma / urothelial carcinoma, in the dog. In some embodiments, the deletion is within exon 12 of BRAF gene, optionally within the amino acid sequence KMLNVTAPTPQQL (SEQ ID NO: 3), and / or in within exon 2 or 3 of a M.AP2K1 gene, optionally within the amino acid sequence FLTQKQKVGE (SEQ ID NO: 4).

The invention relates to a primer for quantitatively detecting V600E mutation of a human BRAF gene based on digital PCR (Polymerase Chain Reaction). The primer comprises nucleotide sequences as shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention also relates to a method for quantitatively detecting the V600E mutation of the human BRAF gene based on the digital PCR. Preferably, the probe comprises a wild type probe of the V600E gene, a mutation site (c.17991800delinsAT) of the V600E gene, a mutation site (c.17991800delinsAC) of the V600E gene, and / or a mutation probe (c.17981799delinsAA) of the mutation site of the V600E gene, and the mutation probe of the mutation site of the V600E gene can be used for detecting the mutation of the V600E gene. According to the method, a vibration microdroplet generation digital PCR (dPCR) technology is combined, and through innovative local law optimization (artificial sequence), remarkable technical advantages and clinical application value are shown in human BRAF gene V600E mutation detection.

The present application belongs to the technical field of intelligent medical treatment, and particularly relates to a RAS, BRAF gene wild type colorectal cancer liver metastasis patient curative effect prediction model based on image group characteristics and application thereof. The present application successfully constructs a model for realizing curative effect prediction of RAS, BRAF gene wild type colorectal cancer liver metastasis patients receiving bevacizumab combined with chemotherapy treatment in the late first line based on CT image group characteristics before treatment: the enhanced CT image group data before initial treatment of patients with advanced colorectal cancer liver metastasis at the time of initial diagnosis is collected, 7 image group characteristics are obtained by using 1000 times Lasso-Logistic analysis, and an image group prediction model is constructed by using a multi-factor logistic regression method. The model constructed by the present application has important clinical application and popularization value from the clinical actual problem.

This invention, entitled "A Biomarker Detection Reagent, Kit, and Application for Colorectal Cancer Gene Mutation Detection," belongs to the field of biomedical technology. The technical problem to be solved is to provide a biomarker detection reagent capable of comprehensively detecting colorectal cancer gene mutations while ensuring high sensitivity and high specificity, thus addressing the difficulty in simultaneously achieving comprehensive site coverage, high sensitivity, high specificity, and high accuracy in existing technologies. The key technical solution is a biomarker detection reagent for colorectal cancer gene mutation detection, comprising a combination of amplification primers for detecting mutation sites in KRAS, NRAS, PIK3CA, and BRAF genes. The amplification primer combination includes primers for amplifying blocked mutation systems and ordinary primers.

Provided is a methylation marker for gastric cancer detection. Provided are 28 differentially methylated regions (DMRs) for diagnosing or assisting with the diagnosis of cancer, and an ELMO1 gene and a KCNA3 gene with a better performance are selected from these 28 DMRs as preferred methylation markers for detecting gastric cancer. Provided is an accurate, simple and economical means for the early screening of gastric cancer, which can improve the detection rate of gastric cancer, particularly early gastric cancer, in gastric cancer high-risk populations and populations undergoing routine physical examinations, thereby improving the survival rate of gastric cancer patients, while saving on substantial medical expenses and alleviating the medical burden.

The invention provides a tetrahedral framework nucleic acid compound for Braf gene silencing as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The tetrahedral framework nucleic acid compound disclosed by the invention is tetrahedral framework nucleic acid loaded with siRNA; the forward sequence of the siRNA is shown as SEQ ID NO.8, and the reverse sequence of the siRNA is shown as SEQ ID NO.7. The compound disclosed by the invention can be enriched at a tumor site, is effectively taken by cancer cells, and shows a good synergistic anti-tumor effect by inhibiting Braf expression, inhibiting proliferation and invasion of cancer cells, promoting cell apoptosis, inhibiting activation of an MEK-ERK signal channel and improving the mitochondrial dysfunction and DNA damage level. Meanwhile, the compound disclosed by the invention has good biological safety and biocompatibility. Therefore, the compound disclosed by the invention is suitable for preparing thyroid cancer related medicines and has a good industrial application prospect.

The invention provides a deaminase, a base editor containing the same and application of the deaminase and particularly provides a deaminase variant which has better gene editing activity compared with wild type deaminase, can effectively edit a target gene and can effectively treat diseases or diseases of subjects in need of the deaminase variant.

The invention discloses a peripheral blood BRAF gene detection kit and application of the peripheral blood BRAF gene detection kit in preparation of a papillary craniopharyngeal tubuloma early diagnosis preparation. The kit contains a primer BR-F and a primer BR-R which are used for digital PCR (Polymerase Chain Reaction), and a probe BR-WP and a probe BR-MP. The kit can be used for directly detecting BRAF V600E gene mutation by taking peripheral blood as a template, the peripheral blood does not need to be extracted, and the operation is convenient and rapid. The kit can be used for detecting papillary craniopharyngeal tubuloma in peripheral blood, non-invasive detection is realized, and the risk of tissue sampling is avoided.

The invention belongs to the technical field of nucleic acid detection, and particularly relates to a primer, a probe, a DNA template, a kit and a detection method for detecting human BRAF gene mutation. According to the invention, a real-time fluorescent PCR amplification reaction system is established to realize rapid detection of BRAF gene mutation; the operation is simple and the result is easy to read. The amplification of the internal standard substance can monitor the accuracy and reliability of the whole detection process by synchronously amplifying a known amount of internal standard substance, so that the stability of experimental data is ensured; the device plays an irreplaceable role in the aspects of guaranteeing the detection quality and improving the detection efficiency.